Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Express Scripts

Last Updated: March 30, 2023

Details for Patent: 9,999,593

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $100
Remove trial restrictions

Which drugs does patent 9,999,593 protect, and when does it expire?

Patent 9,999,593 protects ZIOPTAN and is included in one NDA.

This patent has seventy-six patent family members in twenty-six countries.

Summary for Patent: 9,999,593
Title:Method and composition for treating ocular hypertension and glaucoma
Abstract: The present invention relates to an ophthalmic aqueous composition containing PGF2.alpha. analogs for treating ocular hypertension and glaucoma, to a method for treating ocular hypertension and glaucoma by administering said composition to a subject in need of such treatment, and to a method for increasing aqueous solubility and stability of PGF2.alpha. analogs in an aqueous composition.
Inventor(s): Reunamaki; Timo (Tampere, FI), Pellinen; Pertti (Lempaala, FI), Oksala; Olli (Tampere, FI), Lehmussaari; Kari (Tampere, FI)
Assignee: SANTEN PHARMACEUTICAL CO., LTD. (Osaka-shi, Osaka, JP) ASAHI GLASS CO., LTD. (Chiyoda-Ku, Tokyo, JP)
Application Number:12/995,351
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,999,593
Patent Claim Types:
see list of patent claims
Formulation; Compound;

Drugs Protected by US Patent 9,999,593

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Thea Pharma ZIOPTAN tafluprost SOLUTION/DROPS;OPHTHALMIC 202514-001 Feb 10, 2012 AT RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,999,593

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
08397513May 30, 2008
PCT Information
PCT FiledMay 28, 2009PCT Application Number:PCT/JP2009/060211
PCT Publication Date:December 03, 2009PCT Publication Number: WO2009/145356

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.